Telix Pharmaceuticals (TLX) Common Equity (2023 - 2024)

Telix Pharmaceuticals (TLX) has disclosed Common Equity for 2 consecutive years, with $371.6 million as the latest value for Q4 2024.

  • Quarterly Common Equity rose 283.32% to $371.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $371.6 million through Dec 2024, up 283.32% year-over-year, with the annual reading at $371.6 million for FY2024, 283.32% up from the prior year.
  • Common Equity for Q4 2024 was $371.6 million at Telix Pharmaceuticals, up from $96.9 million in the prior quarter.
  • The five-year high for Common Equity was $371.6 million in Q4 2024, with the low at $96.9 million in Q4 2023.